Information Provided By:
Fly News Breaks for May 27, 2016
KPTI
May 27, 2016 | 08:15 EDT
Raymond James analyst Christopher Raymond initiated Karyopharm with an Outperform and $13 price target. Raymond said Karyopharm is close to a value creation period with key trial read outs that can help advance lead compound selinexor and transition Karyopharm to a commercial entity. Further, its wholly-owned, novel technology platform with an experienced management team and an attractive valuation make shares a compelling investment, the analyst added.
News For KPTI From the Last 2 Days
There are no results for your query KPTI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.